Atrial Fibrillation in Women: Under-Diagnosed, Differently Symptomatic, More Stroke-Prone

She was 54 and had been told for two years that her symptoms were perimenopause. The fatigue, the breathlessness walking up two flights of stairs, the occasional sensation that her heart was doing something irregular. Her hot flash count was noted at every visit. Her heart rhythm had not been checked.

Her 7-day Holter, finally ordered when her breathlessness worsened, showed paroxysmal atrial fibrillation with episodes lasting 4-8 hours. She had been in AF on and off for months. Nobody had looked.

What atrial fibrillation is and how it occurs

Atrial fibrillation is a cardiac arrhythmia characterized by disorganized electrical activation of the atria, the two upper chambers of the heart. Instead of the normal organized P-wave firing from the sinoatrial node, thousands of electrical wavelets fire chaotically across the atrial tissue. The result: the atria quiver rather than contract, sending irregular and rapid impulses to the AV node, which passes them down to the ventricles. The heart beats rapidly and irregularly. 5 / Solid

The immediate hemodynamic consequences: loss of atrial contraction reduces cardiac output by 15-25% (the atrial “kick” contribution to ventricular filling is lost). Heart rate, now irregularly rapid, impairs efficient ventricular filling. In women with pre-existing diastolic dysfunction, more common in women than men , these hemodynamic effects are more symptomatic.

The long-term consequence: blood pools in the left atrial appendage, a small anatomical pouch of the left atrium , during fibrillation, where it can form clots. These clots can embolize to the brain, causing cardioembolic stroke. AF is responsible for approximately 15% of all strokes in the general population and a higher proportion in women over 75. 5 / Solid

Why women present differently and get diagnosed later

The classic AF symptom taught in cardiology training is palpitations, the awareness of the heart beating rapidly and irregularly, described as pounding, fluttering, or skipping. Many patients report this. Women with AF are less likely to report it as their primary symptom.

Women with AF are more likely to present with: 5 / Solid

• Fatigue and reduced exercise tolerance
• Breathlessness, at activity levels that were previously comfortable
• Vague chest discomfort or pressure
• Dizziness or lightheadedness
• Cognitive symptoms (difficulty concentrating)

These symptoms have wide differential diagnoses in a perimenopausal woman: anemia, thyroid dysfunction, deconditioning, perimenopause, anxiety. Each of these is a reasonable consideration. But AF is less likely to be on the differential because the symptom profile does not match the textbook palpitation picture.

The consequence is diagnostic delay. In registry data, women with AF are diagnosed at older ages than men, after longer symptom duration, and with more established AF burden at the time of first diagnosis. 5 / Solid This matters because AF detected early, when it is paroxysmal and the atrium has not yet remodeled from chronic arrhythmia , is easier to treat and more amenable to ablation.

Why women have higher stroke risk from AF

Female sex earns one point on the CHA₂DS₂-VASc score, the validated tool used to determine stroke risk and anticoagulation indication in AF. 5 / Solid

The CHA₂DS₂-VASc score:

• C: Congestive heart failure (1 point)
• H: Hypertension (1 point)
• A₂: Age 75 or older (2 points)
• D: Diabetes (1 point)
• S₂: Prior Stroke or TIA (2 points)
• V: Vascular disease (1 point)
• A: Age 65-74 (1 point)
• Sc: Female Sex (1 point)

Female sex is built into the risk calculation because women with AF have higher stroke rates than men with equivalent AF burden and equivalent traditional risk factor profiles.

The reasons are incompletely understood. Contributing factors include: women tend to be older at AF diagnosis (age itself is the dominant stroke risk factor in AF); women with AF have higher rates of diastolic dysfunction and left atrial dysfunction that may impair atrial emptying; and there may be sex-specific differences in coagulation that influence stroke risk in AF. 4 / Promising

Practically: a woman with no other risk factors scores 1 point for sex alone. Adding any single additional risk factor (hypertension, age 65, diabetes, vascular disease) brings her to 2 points, the threshold where guidelines recommend anticoagulation. Women reach the anticoagulation indication threshold after fewer co-morbidities than men.

Perimenopause and AF: a connection that is underappreciated

Perimenopause creates a substrate for AF in susceptible women through multiple mechanisms:

Autonomic dysregulation. The sympathetic nervous system dysregulation of perimenopause, elevated basal sympathetic tone, exaggerated stress responses, hot flash-associated catecholamine surges , creates atrial ectopy and increases the probability of AF triggers. AF is frequently initiated by atrial premature beats that arise in heightened sympathetic states.

Hot flash-triggered AF. Each significant nocturnal or daytime hot flash is an acute sympathetic event with elevated catecholamines. In women with atrial vulnerability (often subclinical before AF is diagnosed), these events can trigger paroxysmal AF episodes. Women who report palpitations coinciding with hot flash events warrant specific AF monitoring during vasomotor episodes.

Sleep disruption and atrial remodeling. Chronic sleep fragmentation from nocturnal hot flashes and progesterone-mediated insomnia increases circulating inflammatory markers and promotes atrial structural remodeling, changes in atrial tissue that increase AF susceptibility.

Rising blood pressure. Blood pressure rises in perimenopause. Hypertension is the strongest modifiable risk factor for AF development. Even borderline pressure elevations in the 40s compound AF risk over the decade.

Monitoring: when to look

In a woman 45-65 with any of the following, AF should be specifically excluded with prolonged cardiac monitoring:

• New or worsening fatigue, breathlessness, or exercise intolerance
• Palpitations, even those attributed to hot flashes or anxiety , particularly if sustained, associated with lightheadedness, or occurring at rest
• Prior known AF risk factors: hypertension, obesity, sleep apnea, heavy alcohol use
• An Apple Watch or wearable notification of “irregular rhythm” or possible AF

The minimum monitoring duration for episodic symptoms: 30-day event monitor rather than 24-hour Holter. Paroxysmal AF that occurs once or twice weekly is frequently missed on a 24-hour monitor and reliably captured on a 30-day monitor.

Treatment considerations in women

Rate vs. rhythm control. The choice between rate control (slowing the ventricular response to AF, accepting that AF continues) and rhythm control (attempting to restore and maintain sinus rhythm with medication or ablation) depends on symptoms, hemodynamic tolerance, and patient preference. Women with more symptomatic AF, which is more common in women given the AF-diastolic dysfunction interaction , often benefit from rhythm control over rate control. 4 / Promising

Catheter ablation. Ablation is the most effective rhythm control strategy for paroxysmal and early persistent AF. Historically, women have had lower ablation success rates and higher complication rates than men. This difference is attributable partly to anatomical factors (smaller atria relative to catheter size), partly to referral delays that mean women present with more advanced atrial remodeling, and partly to underrepresentation in early AF ablation trials. Contemporary data shows improved outcomes in women with experienced operators and appropriate catheter sizing. The conversation about ablation should not be framed differently for women, the indication criteria are the same; the outcomes discussion should include sex-specific data.

Anticoagulation. For women with CHA₂DS₂-VASc score 2 or above (which, given the sex point, requires only one additional risk factor), anticoagulation is indicated. Direct oral anticoagulants (DOACs: apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin for most patients given lower bleeding risk and more consistent anticoagulation. Women have lower rates of anticoagulation initiation than men with equivalent CHA₂DS₂-VASc scores, a sex disparity in treatment documented across registry studies.

Subclinical AF and the monitoring gap

Not every episode of AF announces itself. Subclinical AF — arrhythmia detected by implanted cardiac devices or continuous wearable monitors before the patient has become aware of symptoms — is increasingly recognized as a clinically significant entity. The LOOP-AF trial established that subclinical AF detected by implanted loop recorders carries a stroke risk comparable to clinically detected AF, meaning the absence of perceived palpitations does not indicate the absence of thromboembolic risk. 5 / Solid

Consumer-grade wearables, including Apple Watch and a growing number of competitor devices with photoplethysmography or single-lead ECG capability, can detect irregular rhythm patterns consistent with AF. This is a genuine advance in early detection access. However, a wearable notification of irregular rhythm is not a diagnosis of AF. It is a prompt to seek confirmatory evaluation. A 12-lead ECG or a dedicated cardiac monitor capturing the rhythm during an irregular episode is required before anticoagulation decisions or other treatment can follow. Women who receive wearable alerts should not dismiss them, but should bring the alert, and the rhythm strip if available from the device, to a physician for formal assessment.

For women who have already had a cryptogenic stroke or TIA — a stroke with no identified cause despite standard workup — the monitoring question is particularly consequential. The EMBRACE trial and the CRYSTAL-AF trial independently demonstrated that extended cardiac monitoring after cryptogenic stroke identifies AF in approximately 30% of patients at three years of follow-up, compared with under 5% identified by standard short-term monitoring. 5 / Solid This means the majority of AF-related cryptogenic strokes would be missed by the 24- or 30-day monitors that remain standard of care in many stroke units.

The clinical implication: a woman with a prior unexplained TIA or ischemic stroke warrants consideration of an implanted loop recorder if a 30-day external monitor has been negative. The negative 30-day result does not close the question. It opens it. Paroxysmal AF can be infrequent enough that months of continuous monitoring are required to capture it, and the consequence of missing it — a second cardioembolic stroke in an anticoagulated-eligible patient who was never anticoagulated — is severe.

AF and cognitive risk: a sex-specific concern

The cardiac consequences of atrial fibrillation are well publicized. The neurological consequences receive less attention, and for women, there is emerging evidence that this gap in the clinical conversation may carry specific cost.

Across multiple large cohort studies, AF is independently associated with a 40–60% increased risk of dementia. 5 / Solid The association holds after adjusting for overt clinical stroke, meaning it is not fully explained by the visible stroke events that AF can cause. The ARIC cohort (Atherosclerosis Risk in Communities), one of the largest long-running cardiovascular epidemiology studies in the United States, found that AF is independently associated with accelerated cognitive decline across multiple cognitive domains including memory, executive function, and processing speed.

The sex differential within this association is a more recent and active area of investigation. Data from MESA (Multi-Ethnic Study of Atherosclerosis) and ARIC both suggest that women with AF carry higher dementia risk than men with AF when compared at equivalent AF burden and equivalent traditional risk factor profiles — paralleling the pattern seen with stroke risk. 4 / Promising These findings are not yet sufficient to alter clinical guidelines, but they are robust enough to inform the clinical conversation.

The mechanisms are multiple and likely additive. Overt cardioembolic stroke from AF is the most visible pathway, but it is not the only one. Silent cerebral microemboli — small embolic events that do not produce detectable clinical stroke but accumulate over time — have been documented in AF patients on neuroimaging. Cerebral hypoperfusion during rapid and irregular ventricular rates can impair cerebral autoregulation. Hypertension, which frequently coexists with AF, causes cerebral microangiopathy that is additive to the direct AF-related pathways.

The clinical implication for women with AF: cognitive symptoms — difficulty with word retrieval, concentration, memory, or processing — are not incidental. They warrant neurological evaluation and should prompt a hard look at whether stroke prevention is optimized. Anticoagulation matters for the brain as well as for the heart. There is emerging evidence from registry and observational data that anticoagulation use in patients with AF is associated with reduced dementia risk, likely through reduction of both overt and silent thromboembolic burden. 4 / Promising This is not yet a randomized trial finding, but the directionality is consistent enough to weigh when evaluating anticoagulation candidates.

What to do this week

The evidence about AF in women is clinically actionable. These steps do not require a specialist referral to initiate.

1. Get an arrhythmia evaluation if you have unexplained fatigue, breathlessness, or palpitations — and ask specifically for extended monitoring, not just a 24-hour Holter. A 24-hour Holter captures rhythm for one day. Paroxysmal AF that occurs once or twice per week will be missed. A 14- or 30-day cardiac event monitor captures enough time to detect intermittent arrhythmia that would be invisible on a shorter study. Ask specifically: “I would like a 30-day event monitor, not just a 24-hour Holter.” If your physician is unfamiliar with the distinction, ask for referral to a cardiologist or electrophysiologist.

2. Know your CHA₂DS₂-VASc score and ask your physician to walk through it with you. As a woman with AF, you start at 1 point. Ask what other factors are contributing to your score — hypertension, age, prior stroke, diabetes, vascular disease each add points — and ask directly whether your current score is above the threshold where anticoagulation is indicated. Understanding your own score shifts you from a passive recipient of a decision to an active participant in it.

3. If you use a smartwatch that has irregular rhythm alerts, take the alert seriously. Print the notification. If your device generated a rhythm strip, bring that as well. Bring it to your physician and ask for formal rhythm evaluation, not reassurance. A wearable alert does not diagnose AF, but it does not deserve dismissal either. Many women with AF have their first documented arrhythmia flag come from a consumer device, and the appropriate response is a 12-lead ECG and extended monitoring, not a normalized explanation.

4. Tell every future provider you have AF, and ask for it to be listed on your active problem list. AF can be buried in a cardiology consultation note and become invisible to a primary care provider, an urgent care physician, or an emergency physician who later sees you. This matters at every care transition — anticoagulation status needs to be visible, and the arrhythmia context shapes decisions about other medications. Ask specifically: “Can you make sure atrial fibrillation is on my active problem list in the chart, not just in old notes?”

5. Ask about anticoagulation if you have AF and have not been started on it. If your CHA₂DS₂-VASc score is 2 or above, ask your physician directly why anticoagulation has not been initiated — or if it has, confirm it is at the appropriate dose and being monitored appropriately. Women with AF are anticoagulated at lower rates than men with equivalent CHA₂DS₂-VASc scores across registry and claims data. This is not a guideline-concordant disparity. Advocating for your own anticoagulation evaluation is appropriate and is not equivalent to asking for a specific drug or dose — those remain clinical decisions for your physician.

Related reading

For the palpitations differential (when is it AF vs. vasomotor vs. anxiety): Heart Palpitations in Perimenopause.

For the perimenopause cardiac risk context: Your Doctor Said You Are Safe Until Menopause.

For HFpEF, the heart failure that commonly coexists with AF in women: HFpEF: The Heart Failure With a Normal Ejection Fraction.